Radioimmunotherapy as Front-Line Treatment for Follicular Lymphoma

New research suggests that frontline radioimmunotherapy would benefit patients with follicular lymphoma.

United Kingdom researchers recruited 74 patients with a median age of 61 (ranging from 28 to 80 years of age) who required initial therapy.

Among these research subjects:

  • 78 percent had stage III-IV disease
  • 32 percent intermediate disease
  • 44 percent high-risk disease (according to FL International Prognostic Index).

Treatment consisted of two doses of 90Y-IT (11.1 MBq/kg, also known as Zevalin) administered 8 to 12 weeks apart. Patients with more than 20 percent lymphoma infiltration of bone marrow received one infusion per week for four consecutive weeks of rituximab (375 mg/m2) and proceeded to fractionated radioimmunotherapy only if a repeat bone marrow biopsy demonstrated clearing of lymphoma to less than 20 percent involvement.

The primary end point was end of treatment response of the intention-to-treat population. Secondary objectives were safety and progression-free survival.

Results encouraging

The initial overall response rate was 94.4 percent (68 of 72 patients) with combined complete response (CR/CRu) of 58.3 percent(42 of 72 patients).

Nine patients subsequently improved response, making an ORR of 95.8 percent (69 of 72 patients) and CR/CRu of 69.4 percent (50 of 72 patients).

At a median follow-up of 3.1 years, estimated three-year PFS is 58 percent, treatment-free survival is 66 percent, and overall survival is 95 percent.

However, the median PFS is 40.2 months, and 30 patients have experienced disease progression and 24 have required further treatment.

Side effects were extremely low compared to other studies involving combination chemotherapy.

"This was the first study to look at giving two fractions of radioimmunotherapy as an initial treatment in follicular lymphoma," said Tim Illidge, MRCP, FRCR, FRCPath, Ph.D., of the University of Manchester in the United Kingdom. "We wanted to assess its safety and effectiveness in a group of high-risk patients who conventionally have done less well."

While encouraged by many of the outcomes, Illidge said further studies are needed "in larger numbers of patients to fully compare this treatment to the standard treatment of six to eight cycles of chemotherapy."

The findings appeared in the Journal of Clinical Oncology.

Source: JCO

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Sitemap